跳至主要内容
临床试验/NCT00209027
NCT00209027终止不适用

Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia

Emory University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2005年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
20
试验地点
1
主要终点
BOLD Activation During fMRI Scanning During Performance of a Monetary Reward Task

研究概览

简要总结

The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.

详细描述

TITLE: Aripiprazole effects on reward processing in deficit syndrome schizophrenia Principal Investigator: Erica Duncan, M.D.

Background- This is a study of the way people with schizophrenia may feel when they get rewards. Certain parts of the brain play a part in people feeling happy when they win some sort of reward or have a good thing happen to them. Some people with schizophrenia may have trouble feeling pleasure because part of their brains, the frontal cortex, may not work properly. We are doing this study to understand how the frontal cortex works in people with and without schizophrenia when they are trying to win a reward. We will use a special kind of brain scan called Functional Magnetic Resonance Imaging (fMRI) to show the brain working in action. fMRI scanning uses a big magnet to take special pictures of the brain.

A new medicine called aripiprazole has been approved by the Food and Drug Administration for treating symptoms of schizophrenia. This medicine has a new mechanism of action that helps neural functioning in the part of the brain that is involved with planning and goal setting. We think this new medication may help with brain processing of rewards. We are therefore studying the brain with fMRI scans before and during treatment with this aripiprazole.

Objective- The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.

Research Plan-Aim 1. Define impairments in the neural correlates of reward processing in primary deficit syndrome schizophrenics compared to normal controls.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
盲法
None

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Diagnosed with schizophrenia
  • Age 20-50
  • Right handed

排除标准

  • No current or past drug or alcohol problems (dependance or abuse)
  • Not color blind
  • Control Subjects:
  • Inclusion Criteria:
  • Age 20-50
  • Right handed
  • Exclusion Criteria:
  • No current psychiatric problems
  • No current or past drug or alcohol problems
  • Not color blind

研究组 & 干预措施

schizophrenia subjects

Experimental

Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.

干预措施: fMRI (Other)

schizophrenia subjects

Experimental

Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.

干预措施: Aripiprazole (Drug)

结局指标

主要结局

BOLD Activation During fMRI Scanning During Performance of a Monetary Reward Task

时间窗: Baseline and 12 weeks

fMRI BOLD activation during a reward task will be compared between schizophrenia subjects and controls at Baseline. Schizophrenia subjects will switch their baseline medication to aripiprazole and their BOLD activation during the reward task at Baseline will be compared to the endpoint scan.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Erica Duncan, MD

Associate Professor

Emory University

研究点 (1)

Loading locations...

相似试验